Evidence map›Paper›PMID 37446224›Full record

ArticleInternational journal of molecular sciences2023

Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-One-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity.

Yogesh Mahadu Khetmalis, Ashna Fathima, Markus Schweipert, Cécile Debarnot, Naga Venkata Madhusudhan Rao Bandaru, Sankaranarayanan Murugesan, Trinath Jamma, Franz-Josef Meyer-Almes, Kondapalli Venkata Gowri Chandra Sekhar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Synthesis, evaluation ofRSC advances · 2025
    Article
  3. Discovery and Characterization of Novel Non-Hydroxamate HDAC11 Inhibitors.International journal of molecular sciences · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yogesh Mahadu KhetmalisDepartment of Chemistry, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Hyderabad 500078, Telangana, India.
Ashna FathimaDepartment of Biological Sciences, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Hyderabad 500078, Telangana, India.ORCID 0000-0003-4789-741X
Markus SchweipertDepartment of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Haardtring 100, 64295 Darmstadt, Germany.
Cécile DebarnotDepartment of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Haardtring 100, 64295 Darmstadt, Germany.
Naga Venkata Madhusudhan Rao BandaruDepartment of Chemistry, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Hyderabad 500078, Telangana, India.
Sankaranarayanan MurugesanMedicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science Pilani, Pilani Campus, Pilani 333031, Rajasthan, India.
Trinath JammaDepartment of Biological Sciences, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Hyderabad 500078, Telangana, India.
Franz-Josef Meyer-AlmesDepartment of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Haardtring 100, 64295 Darmstadt, Germany.ORCID 0000-0002-1001-3249
Kondapalli Venkata Gowri Chandra SekharDepartment of Chemistry, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Hyderabad 500078, Telangana, India.
Birla Institute of Technology and Science - Hyderabad Campus · INTechnische Universität Darmstadt · DEBirla Institute of Technology and Science, Pilani · IN

Funding

Birla Institute of Technology and Science, Pilani OPERA grantCouncil of Scientific and Industrial Research 02(392)/ 21 / EMR IISERB-ECRA ECR/2017/001583State of Hesse LOEWE Priority Program TRABITA
6 · The paper itself

Abstract

A series of novel quinazoline-4-(3H)-one derivatives were designed and synthesized as histone deacetylase 6 (HDAC6) inhibitors based on novel quinazoline-4-(3H)-one as the cap group and benzhydroxamic acid as the linker and metal-binding group. A total of 19 novel quinazoline-4-(3H)-one analogues (

Indexed as

Antineoplastic AgentsCell Line, TumorCell ProliferationHistone Deacetylase 1Histone Deacetylase 6Histone Deacetylase InhibitorsMolecular StructureQuinazolinesStructure-Activity RelationshipAntineoplastic AgentsHistone Deacetylase 1Histone Deacetylase 6Histone Deacetylase InhibitorsQuinazolinescancerhistone deacetylasequinazoline-4-(3H)-onesmall-molecule inhibitors

Identifiers

PMID37446224
PMCPMC10341573
OpenAlexW4383105509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.